Our Research

Our Research

>> Research Departments
>> Find Clinical Trials
>> Our Publications
>> Our Research Collaborations


Contact Details

  Street address:
Level 11, KGV Building
Missenden Road
CAMPERDOWN NSW 2050
 
Postal address:
Post Office Box M30
Missenden Road NSW 2050

Phone: (02) 9515-6111
Fax: (02) 9515-9610

Online Feedback

AW Gastroenterology and Liver Centre

Our Research

BACKGROUND
Chronic liver damage affects up to 20 per cent of Australians and liver cancer, often caused by chronic liver damage, is one of the fastest growing diseases in our community. Chronic liver damage has many causes including viral infections (hepatitis B and C), toxins, and genetic, metabolic and autoimmune diseases. Diseases of the gastrointestinal system include inflammatory bowel diseases, gastrointestinal bleeding and bowel cancer. These are responsible for up to 2% of GDP of western societies thus resulting in significant morbidity and mortality in our communities.

Our research is based on the premise of close interaction between the laboratory and our patients. The overall approach is complimentary between studies in patients, studies in animals and studies in vitro (the test tube). Eg: when observations are made in patients, we develop models to study disease processes and then use these models together with functional studies in vitro, to obtain a greater understanding. The overall aim is to use such data to explore new therapeutic horizons and/or new diagnostic procedures or new monitoring processes in human disease.

OUR RESEARCH: HOW DOES IT IMPACT ON COMMUNITY HEALTH?
Our research has major impact, particularly in the areas of liver transplantation, hepatitis virus infections, liver cancer, inflammatory bowel disease, gastrointestinal bleeding and diabetes. Our understanding of how the immune system interacts with the liver is crucial to design strategies to promote acceptance of a new liver without rejection, whilst on the other hand promote processes to eliminate viral infection. The work on liver injury itself will enable us to develop therapeutic strategies to stop the progression of liver injury and the development of liver cancer (the fourth most common human malignancy). We have already made a major contribution to the field of new diabetes therapies and have clarified best practice treatments for inflammatory bowel disease, liver cancer and gastrointestinal bleeding. We have also developed new endoscopic procedures for the small intestine and biliary tract. Thus the AW Morrow Centre has a distinguished role in a wide spectrum of gastrointestinal and liver diseases that have a major impact on human health.

RESEARCH THEMES AT THE LABORATORY LEVEL

  1. The role of liver stem cells in liver disease. This work is lead by Prof McCaughan and has defined a novel characteristic of liver stem cells within the inflammatory/fibrotic niche that develops during chronic liver disease and cirrhosis. This work has found that a cellular structure, called the primary cilium, transducers signals from the local environment to the liver stem cell compartment leading to proliferation and migration of cells. One of the key mediators is the hedgehog molecule and we have defined this hedgehog pathway and the response of these cells in mouse liver models and more recently human disease. We have also worked in collaboration with the Cellular and Molecular Regenerative Institute at Edinburgh University to develop a unique mouse model where the Primary Cilia structures can be depleted in the stem cell compartment. We are currently in the process of inducing liver injury and liver cancer to explore the exact nature of these signals. This work will be very important as stem cell therapies are emerging to treat chronic associated liver diseases and indeed one of our collaborators in Edinburgh, Prof Stuart Forbes, has shown that these cells can repopulate an injured liver and replace hepatocytes, significantly improving liver function.
     
  2. The role of molecular pathways in primary liver cancer. This work in collaboration across the whole of the centre lead by Prof Geoff McCaughan, A/Prof Mark Gorrell and A/Prof Nick Shackel has been exploring pathogenic pathways in hepatocellular cancer. As mentioned earlier, hepatocellular cancer is the fastest growing cancer in the Western World and has a survival rate of only less than 15% at five years and there is no significant new therapy in the last five years to combat this disease. We have used knockout mice to identify five different mechanisms that could be affecting outcomes in experimental liver cancer and also developed stable markers to project the outcomes in human liver cancer. This research includes reduced liver cancer development in knockout mice for SP1 and microRNA 181a, whilst endothelial gene SENEX knockout mice develop more Liver cancer and the stomal cell marker Fibroblast activation protein is a therapeutic target. We believe that such multiple approaches to liver cancer is crucial to understand the complex nature of the problem and to produce new effective therapeutics.
     
  3. The role of the Oligopeptidase Gene family in liver diseases and cancer. This work is lead by Mark Gorrell and has made major breakthroughs in the study of Type II Diabetes associated with liver disease, liver cancer and also liver fibrosis. The work has been able to show that the serum Fibroblast Activation Protein (FAP) is able to delineate the risks for progressive liver disease in diabetes associated liver disease in humans. Furthermore, FAP knockout mice have improved liver injury and liver fibrosis. Another member of the family DPP9 regulates adhesion and cell migration in cancer cells and is emerging as a key pathogenic pathway in general carcinogenesis.
     
  4. Immunology and understanding liver transplant tolerance. This work, carried out by Dr Patrick Bertolino and A/Prof David Bowen, has made major breakthroughs in the understanding of how liver transplants are spontaneously accepted and the potential to select humans for immunosuppressive withdrawal. The work has identified that liver cytotoxic T cells which would normally reject and damage the liver are eliminated by the liver in the early phases of transplantation by a normal mechanism whereby liver cells actually eat the activated immune cells. The process has been named by us as suicidal empiriopolesis. The work also increases our understanding of how viruses and autoimmune liver diseases are associated with progression to chronicity and non-resolution of disease.

    In collaboration with Professor Heath at the Walter and Eliza Hall Institute in Melbourne Dr Bertolino has furthermore identified blood memory cells that reside in the liver. These cells are very efficient in protecting against malaria infection and this potentially provides new strategies to protect individuals against pathogens that attack the liver such as malaria and other viruses. More recently, a novel type of macrophage cell has been discovered by Dr Bertolino's group, where a novel liver macrophage which is located in the liver capsule is currently under examination for playing a role in protecting the liver against pathogenic effects from the peritoneal cavity.

    Highlights of Laboratory Research
    The above programs have resulted in much novel research some of which is highlighted below.
  • DPP4 is pro-fibrotic in mouse liver, in the highly regarded journal Immunology and Cell Biology, and that the reduction in fibrosis is accompanied by fewer clusters of B cells in the liver. A diabetes drug that inhibits DPP4 dampens liver fibrosis.
  • The FAP and DPP4 enzymes both degrade neuropeptides in human serum, and these neuropeptides have different locations in human liver with cancer.
  • Blood tests for FAP and for DPP4 in fatty liver and diabetes patients are useful in assessing liver injury severity.
  • The amount of FAP in blood drops about 30% following liver transplant. This further indicates that our FAP assay is a useful diagnostic of the extent of fibrosis.
  • FAP and DPP4 in plasma are less than or the same as healthy people in rheumatoid arthritis and scleroderma patients, which reinforces the specificity of FAP for liver fibrosis.
  • Showed that a variant in the human FAP gene is not harmful to patients, so using FAP as a drug target is probably going to be safe.
  • We developed a new, more rapid model of primary liver cancer. In this model, the liver rapidly develops fibrosis when mice are given a toxin and fed sweet, fatty food. This new model is making it much faster to test potential therapies.
  • We made a DPP9-deficient mouse strain, and showed that it dies at birth and has an altered immune system.
  • DPP9 regulates cell adhesion and cell migration. This contributes to understanding how tumours grow. This paper was the subject of a Centenary Institute media release. A detailed new analysis of proteins that are degraded by the DPP9, DPP8 and DPP4 enzymes may reveal new functions of these enzymes.
  • Obtained very promising results from a new prodrug that target cells that make FAP, in a mouse model of liver fibrosis.
  • Published reviews on liver cancer, and on DPP4 family biochemistry and four invited book chapters.
  • Students Yiqian Chen, Hui Emma Zhang and Elizabeth Hamson were awarded their PhDs and Margaret Gall submitted her PhD. Topics were on the FAP and DPP9 enzymes.
  • A publication in the prestigious journal Proceedings of the National Academy of Science USA. A major study showing that the outcome of the immune response against a liver protein is influenced by the amount of protein expressed by liver cells. Reflecting the importance of this work, we have been invited to write a major review article on this topic in one of the top 3 Hepatology journals. In this review, we explain how our findings could explain why some viruses infecting the liver (e.g. Hepatitis B and C viruses) are not efficiently cleared by the immune system and cause a chronic disease.
  • An invited review on our recent findings showing how liver cells can eat and kill immune cells. We proposed that this cell cannibalism explains the poor immune response observed during infections by liver-infecting pathogens.
  • Michael Wong was awarded a New Staff/Early Career Researcher grant in 2015 by the University of Sydney Medical School and the Young Investigator award by the Gastroenterology Society of Australia in 2016. He also received a prize for the best presentation of Early Career Researchers at the 7th Annual branch Meeting of the Australian Society of Immunology NSW/ACT.
  • In 2016, Michelle Vo from our Liver Immunology Program was awarded her PhD and her PhD work was published in 2016 in one of the top 3 Hepatology journals (Journal of Hepatology).
  • Publication of a major article in a special issue of Frontiers in Microbiology, reviewing the immune response against the liver form of the parasite that causes malaria that infects 1.2 billion people worldwide. This parasite is transmitted by mosquitoes and infects 1.2 billion people worldwide. This article has been the most viewed article (out of 21) in this special issue.
  • With collaborators in Melbourne (WR Heath and I Caminschi), lead in 2016 to an important study in the top immunological journal 'Immunity' that identifies a population of white blood memory cells that resides in the liver that is very efficient to protect against the malaria causing pathogen. This provides new strategies to vaccinate individuals against pathogens that target the liver (malaria, hepatitis viruses).
  • An invited review published in Clinical and Translational Immunology in which we discussed the mechanisms by which the liver graft dampens the host immune response and proposed that immune events occurring during the first days after liver transplantation are critical in influencing the outcome of the immune response.

RESEARCH THEMES AT THE CLINICAL LEVEL

  1. Chronic Liver Disease and Liver cancer Clinical and observational trials - Associate Professor Simone Strasser leads our clinical trials program in liver disease. The studies have been in the following areas:

    a. New therapies for Hepatitis B , Hepatitis C and Hepatocellular cancer.
     
    In particular members of the unit have been involved in international studies that have delivered new treatments for patients with hepatitis C infection in mild through to advanced liver disease. These include SOLAR-2 studies and others that have lead to publications in the Lancet Infectious Disease and the Annals of Internal Medicine.

    Chief Investigator studies in Australia have lead to the use of the new Hepatitis C treatments in patients with liver failure and undergoing liver transplantation. For the first time we have seen reversibility of HCV related liver failure and the prevention of HCV infection post liver transplant. These new HCV therapies are one of the most exciting advances in the whole of medicine for many years leading the potential to eventually eradicate HCV infection worldwide. We have significant community care nurse lead programs to deliver these therapies to the wider HCV infected populations.

    Professor McCaughan and Associate Professor Strasser have been active participants and leaders in APASL and the International Association for the Study of Liver Disease consensus statements for the treatment and management of hepatitis C.

    b. Analysis of hepatic encephalopathy in advanced liver disease.

    Helen Vidot and Nick Shackel have lead investigator initiated studies in Probiotics to treat resistant encephalopathy whilst Associate Professor Simone Strasser is part of an international study to maximise outcomes for patients with this major debilitating clinical problem.

    c. The role of nutrition in supporting patients with advanced liver disease.

    The Centre has a major interest in the study of nutritional parameters in patients with liver failure. Studies carried out by nutritionists Helen Vidot and Joanne Heyman have defined energy expenditure requirements, the need for protein supplementation and therapies for muscle cramps in our patients.

    d. Novel therapies for Primary Biliary Cirrhosis
     
    Associate Professor Strasser was one of the investigators in an international study of a new treatment for Primary Biliary Cirrhosis published in the New England Journal of Medicine. This new therapy resulted in significant improvement in liver function in such patients and is the first new breakthrough in treatment for this disease in over 30 years.
     
  2. Endoscopy and inflammatory bowel disease research

    These studies are being undertaken by Dr Arthur Kaffes and newly appointed consultants Dr Cris Corte and Dr Payal Saxena. The areas of study are listed below:

    a. Double balloon endoscopy to treat small bowel strictures.
    b. Colonic Polyp detection using new dye techniques.
    c. New therapy for leaks and perforations of the bowel.
    d. New therapy for achalasia, the new POEM procedure.
    e. Double balloon ERCP to treat Biliary Strictures in patients without a native bile duct.
    f. Endoscopic ultrasound procedures to diagnose and treat intra-abdominal collections, tumours and pancreatic cysts.
    g. Development of a screening protocol for development of pancreatic cancer.
    h. Clinical trials for new therapies in Ulcerative Colitis and Inflammatory Bowel Disease.
    i. Introduction of Endoscopic Myotomy for the treatment of Achalasia of the Oesophagus.
     
  3. Outcomes in liver transplantation includes the following studies:
     
    a. Recording of outcomes for Australian Aboriginal and Torres Island people which showed that excellent outcomes can be obtained despite major obstacles in delivering healthcare in remote communities.
    b. Predictions of cancer development in long-term patients under transplantation showing risk factors for the developments of lymphoma.
    c. Analysis of pre-transplant metabolic factors of survival post transplant.
    d. Development of novel non-surgical interventions for the assessment of hepatic artery stenosis and splenorenal shunts following liver transplantation.
    e. The outcomes for liver transplantation in Australia and New Zealand at the local and international level.

Clinical and Observational Trials

Commercially sponsored studies: Studies active 2016:

  1. GS-US-174-0102 A randomized, double-blind, controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant chronic hepatitis B X06-0033
  2. GS-US-174-0103 A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B X06-0034
  3. GS-US-248-122 HepC registry A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection X11-0282
  4. GS-US-248-123 HepC registry A Long Term Follow-up Registry for Subjects Who Did Not Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection X11-0283
  5. A3921139 (Ulcerative Colitis) A Multi-Centre, Open-Label Study Of Cp-690,550 In Subjects With Moderate To Severe Ulcerative Colitis X12-0010
  6. AI 444-046 (HepC follow up study) A long term follow up study of subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic Hepatitis C X12-0223
  7. POISE - 747-301 A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis X12-0303
  8. ELAD VTI-208 A Randomized, Open-Label, Multicentre, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Alcohol-Induced Liver Decompensation (AILD) X13-0159
  9. Bayer 15982 A Randomized, Double Blind, Placebo-Controlled, Multicentre Phase III Study Of Regorafenib In Patients With Hepatocellular Carcinoma (HCC) After Sorafenib X13-0210
  10. ARQ 197-A-U303 A Phase 3, Randomized, Double-Blind Study Of Tivantinib (Arq 197) In Subjects With Met Diagnostic-High Inoperable Hepatocellular Carcinoma (Hcc) Treated With One Prior Systemic Therapy X13-0250
  11. MK-5172-035 A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 +/-Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection X13-0263
  12. GS-US-320-0110 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B X14-0006
  13. Eisai 5501-G000-310/311 A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure X14-0016
  14. M12-999 Open-label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 .Hepatitis C Virus (HCV) Infection X14-0018
  15. MK-5172-052 A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease X14-0020
  16. XL184-309 A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib X14-0084
  17. NGM 14-0104 A Phase 2, Multi-Centre Study To Evaluate Three Doses Of NGM282 Administered For 24 Weeks In Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103 X14-0160
  18. MK-5172-065 A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood Disorders with and without HIV Co-Infection X14-0222
  19. 747-302 A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicentre Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis X14-0373
  20. ABX203-002 A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region X15-0039
  21. M14-868 A Randomized, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II) X15-0133
  22. NGM-15-0105 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Centre Study To Evaluate The Safety, Tolerability, And Efficacy Of Ngm282 Administered For 12 Weeks In Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) X15-0134
  23. PROSPER Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin 550mg X15-0211
  24. MK-5172-017 A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial X15-0268
  25. GS-US-337-1431 A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials X15-0269
  26. GS-US-330-1508 A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects with Chronic Hepatitis B Infection X15-0335
  27. 747-303 A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicentre Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (REGENERATE) X15-0413
  28. M13-594 A Randomized, Open-Label, Active-Controlled, Multicentre Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3) X15-0425
  29. CA209-459 A Randomized, Multi-centre Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma X15-0467
  30. Heparc 2008 A Multicentre, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination with Other Therapeutics in Patients with Chronic Hepatitis B Virus (HBV) Infection (MONARCH) X15-0468
  31. GS-US-367-1172 (POLARIS 2) A Phase 3, Global, Multicentre, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV Infection (POLARIS 2) X16-0022
  32. GS-US-367-1173 (POLARIS 3) A Phase 3, Global, Multicentre, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis X16-0023
  33. GS-US-367-1170 (POLARIS 4) A Phase 3, Global, Multicentre, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS 9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor X16-0024
  34. Receptos RCP01-3101 A Phase 3, multicentre, randomized, double-blind, placebo-controlled trial of oral RPC1063 as induction and maintenance therapy for moderate to severe ulcerative colitis X16-0034
  35. GS-US-367-1171 (POLARIS 1) A Phase 3, Global, Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection (POLARIS 1) X16-0040
  36. M13-596 A Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2) X16-0087
  37. MK-3475-224 A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Hepatocellular Carcinoma who Progressed on or were Intolerant to First Line Systemic Therapy. X16-0088
  38. MK-3475-240 A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) X16-0089
  39. GED-0301-CD-002 A Phase 3, randomized, double-blind, placebo-controlled, multicentre study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn's disease X16-0184
  40. GED-0301-CD-004 A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn's disease X16-0202
  41. JX594-HEP024 A Phase 3 Randomized, Open-Label study comparing Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) followed by sorafenib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy X16-0389
  42. Receptos RCP01-3102 A Phase 3, Multicentre, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis X16-0331
  43. Wallflex A Multi-Centre, Prospective, Randomized Study Comparing Removable, Self-Expanding Metal Stents to Plastic Stents for the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis X15-0254
  44. GS-US-419-3895 Combined Phase 3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of Filgotinib in the induction and maintenance of remission in subjects with moderately to severely active Crohn's Disease
  45. GS-US-419-3896 A long term extension study to evaluate the safety of Filgotinib in subjects with Crohn's Disease
  46. I6T-MC-AMAC (LILLY) A Phase 2, Multicentre, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis
  47. I6T-MC-AMAG (SERENITY) A Phase 2, multicentre, randomized, double-blind, parallel, placebo controlled study of LY3074828 in subjects with active Crohn's Disease (SERENITY)
  48. Legacy (Humira registry study) A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) X16-0444


Investigator-led studies: 

  1. Predict Study (sub-study: Guide) PREDICT: The Influence of Host Genetics and Viral Factors in Chronic Hepatitis C infection; GUIDE: The correlation of IL28B genotypes with patient demographics and disease characteristics in treatment-naïve patients with HCV-2/3 X11-0054
  2. AbbVie all oral HCV Genotype 1 Regimen (LNR) AbbVie All Oral HCV Genotype 1 regimen-The Australian Experience X15-0098
  3. OPERA-C An Observational Prospective Epidemiological Registry in Australia of HCV Liver Disease X15-0465
  4. RPAH Liver Tumour Database (HCC database) - In House Sofosbuvir-Based Regimen without Interferon for Chronic X09-0382
  5. TPU admission after TACE (Amy Chui LNR) The requirement of overnight TPU hospital admission after TACE for HCC X15-0163
  6. Audit of HCC management decisions (James Bergfield LNR) Audit of initial hepatocellular carcinoma management decisions and comparison with AASLD/EASL guidelines (Audit of HCC Decision Making) X15-0188
  7. HepB Community Clinic Acceptability and Feasibility of a Hepatitis B Community Clinic and Description of Patients Attending the Clinic X13-0031
  8. Fibroscan by HepB nurse in GP Practices for HepB Liver Disease Evaluation of the Acceptability, Feasibility and Safety of a Specialist Hepatitis B Nurse Utilising Portable Elastography to Identify Hepatitis B Related Liver Disease in GP Practices X14-0286
  9. Transplant Outcomes (Jo Mitchell LNR) TOSCAR-Transplant Outcomes X15-0070
  10. Donor Liver Utilisation A single centre, retrospective study to examine donor liver utilisation in liver transplantation X15-0398
  11. Alpha 1 antitrypsin deficiency in liver transplant recipients A single centre retrospective descriptive study of alpha 1 anti-trypsin deficiency among adult liver transplant recipients X16-0047
  12. Acute renal impairment post liver transplantation Factors associated with acute renal impairment post liver transplantation
  13. EPOC Protocol Endoscopic Polypectomy On Clopidogrel: a randomized controlled trial (EPOC) X16-0386
  14. Decision Aid for UC Patients A cluster randomised controlled trail of a decision aid for elcerative colitis patients: Enhancing patients' quality of life, empowerment, quality of decision making and disease control X16-0434
  15. Retrospective review of Clinical and Procedual aspects relating to per-oral endoscopy myotomy X16-0408
  16. Retrograde Device Assisted Enteroscopy as a Salvage Procedure for Failed Colonoscopy: the Experience of an Australian Centre X16-0422
  17. PREDICT-UC Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis- a randomised controlled trial (PREDICT-UC)
  18. Pathogenesis of Liver Disease Pathogenesis of human liver disease X13-0436 (prev. X10-0072)
  19. Nutrition and Frailty (Ken Liu LNR) A single centre prospective study to evaluate nutritional status and frailty in patients with liver cirrhosis. X15-0062
  20. Nursing Practice in Advanced Liver disease Pilot Education Program Evaluation X15-0244
  21. TAPESTRY The outcomes of novel therapies for autoimmune hepatitis in patients with suboptimal responses to standard therapy X15-0278
  22. Liver Disease Database Liver Disease Database X15-0441
  23. Falls in Cirrhosis (LNR) A retrospective case-control study to determine independent risk factors for falls in inpatients with cirrhosis
  24. Evaluation Project Tap Clinic 2016 X16-0432
  25. Pathogenesis of Human Liver Disease an Liver Cancer Pathogenesis of Human Liver Disease an Liver Cancer

Research Staff

Investigators/Sub Investigators:

  • Prof Geoff McCaughan
  • A/Prof Simone Strasser
  • A/Prof David Koorey
  • A/Prof Nick Shackel
  • A/Prof David Bowen
  • Dr Emilia Prakoso
  • Dr Peter Lim
  • Dr Anastasia Volovets
  • A/Prof Mark Gorrell
  • Dr Patrick Bertolino
  • Dr Fei Wen Chen
  • Dr Aravind Gokul Tamilarasan
  • Dr Shahila Perveen Aslam
  • Dr Yon Xian Koh

Research Nurses:

  • Ms Janice Pritchard-Jones
  • Ms Barbara Charlton
  • Ms Elizabeth Glynn
  • Ms Susan Hoy
  • Ms Magda Gawrys
  • Ms Margaret Fitzgerald
  • Ms Helen Colinet
  • Ms Susan Mason
  • Ms Sinead Sheils

Clinical trial coordinators:

  • Dr Tatiana Tsoutsman
  • Dr Lisa Lo
  • Ms Aimei Lee
  • Dr Garry Chang

Publications and Presentations

Publication Details:
  1. Wong PF, Gall MG, Bachovchin WW, McCaughan GW, Keane FM, Gorrell MD. Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma. Peptides. 2016 Jan;75:80-95.
  2. Lee A, Rode A, Nicoll A, Maczurek AE, Lim L, Lim S, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2016 Feb;31(2):459-66
  3. Chen J, Wang W, Qi Y, Kaczorowski D, McCaughan GW, Gamble JR, Don AS, Gao X, Vadas MA, Xia P. Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPARγ. Biochim Biophys Acta. 2016 Feb;1861(2):138-47
  4. Chen Y, Gall MG, Zhang H, Keane FM, McCaughan GW, Yu DM, Gorrell MD. Dipeptidyl peptidase 9 enzymatic activity influences the expression of neonatal metabolic genes. Exp Cell Res. 2016 Mar 1;342(1):72-82.
  5. McCaughan GW, Crawford M, Sandroussi C, Koorey DJ, Bowen DG, Shackel NA, Strasser SI. Assessment of adult patients with chronic liver failure for liver transplantation in 2015: who and when? Intern Med J. 2016 Apr;46(4):404-12
  6. Adams LA, Arauz O, Angus PW, Sinclair M, MacDonald GA, Chelvaratnam U, Wigg AJ, Yeap S, Shackel N, Lin L, Raftopoulos S, McCaughan GW, Jeffrey GP; Australian New Zealand Liver Transplant Study Group.. Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant. J Gastroenterol Hepatol. 2016 May;31(5):1016-24
  7. Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016 May 24;11(5):e0155800
  8. McCaughan GW, Munn SR. Liver transplantation in Australia and New Zealand. Liver Transpl. 2016 Jun;22(6):830-8
  9. Vo M, Holz LE, Wong YC, English K, Benseler V, McGuffog C, Azuma M, McCaughan GW, Bowen DG, Bertolino P. Effector T cell function rather than survival determines extent and duration of hepatitis in mice. J Hepatol. 2016 Jun;64(6):1327-38.
  10. Na R, Laaksonen MA, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. J Am Acad Dermatol. 2016 Jun;74(6):1144-1152.e6
  11. Liangpunsakul S, Haber P, McCaughan GW. Alcoholic Liver Disease in Asia, Europe, and North America. Gastroenterology. 2016 Jun;150(8):1786-97.
  12. Köhn-Gaone J, Dwyer BJ, Grzelak CA, Miller G, Shackel NA, Ramm GA, McCaughan GW, Elsegood CL, Olynyk JK, Tirnitz-Parker JE. Divergent Inflammatory, Fibrogenic, and Liver Progenitor Cell Dynamics in Two Common Mouse Models of Chronic Liver Injury. Am J Pathol. 2016 Jul;186(7):1762-74
  13. Na R, Laaksonen MA, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia. Br J Haematol. 2016 Aug;174(4):550-62
  14. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016 Sep;10(5):702-26.
  15. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Al-Mahtab M, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016 Sep;10(5):681-701
  16. Budzinska MA, Tu T, d'Avigdor WM, McCaughan GW, Luciani F, Shackel NA. Accumulation of Deleterious Passenger Mutations Is Associated with the Progression of Hepatocellular Carcinoma. PLoS One. 2016 Sep 15;11(9):e0162586.
  17. Fernandez-Ruiz D, Ng WY, Holz LE, Ma JZ, Zaid A, Wong YC, Lau LS, Mollard V, Cozijnsen A, Collins N, Li J, Davey GM, Kato Y, Devi S, Skandari R, Pauley M, Manton JH, Godfrey DI, Braun A, Tay SS, Tan PS, Bowen DG, Koch-Nolte F, Rissiek B, Carbone FR, Crabb BS, Lahoud M, Cockburn IA, Mueller SN, Bertolino P, McFadden GI, Caminschi I, Heath WR. Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection. Immunity. 2016 Oct 18;45(4):889-902
  18. Ban LA, Shackel NA, McLennan SV. Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016 Mar 14;17(3):376.
  19. Patel K, Tillmann HL, Matta B, Sheridan MJ, Gardner SD, Shackel NA, McHutchison JG, Goodman ZD. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers. Aliment Pharmacol Ther. 2016 Feb;43(3):356-63.
  20. Marcellin P, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, Petersen J, Lee CM, Ma X, Caruntu FA, Tak WY, Elkhashab M, Lin L, Wu G, Martins EB, Charuworn P, Yee LJ, Lim SG, Foster GR, Fung S, Morano L, Samuel D, Agarwal K, Idilman R, Strasser SI, Buti M, Gaeta GB, Papatheodoridis G, Flisiak R, Chan HL. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2016 Nov;44(9):957-966.
  21. Pudipeddi AV, Liu K, Watson GF, Davis RJ, Strasser SI. Cryptococcal osteomyelitis of the skull in a liver transplant patient. Transpl Infect Dis. 2016 Sep 7
  22. Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus. 2016 Aug 19;5(1):1365
  23. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group.. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016 Aug 18;375(7):631-43
  24. Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser SI, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. Scand J Gastroenterol. 2016 Aug;51(8):979-85.
  25. Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016 Jul;44(1):16-34
  26. Najjar Z, Gupta L, Pritchard-Jones J, Strasser SI, Levy MT, Liaw ST, Cowie BC. A survey of Sydney general practitioners' management of patients with chronic hepatitis B. Med J Aust. 2016 Feb 1;204(2):74.e1-4
  27. Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; Study 149 Investigators.. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B. Gastroenterology. 2016 Jan;150(1):134-144.e10
  28. Liu K, Joshi V, Saxena P, Kaffes AJ. Predictors of success for double balloon-assisted endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anastomosis. Dig Endosc. 2016 Sep 17.
  29. Henderson JM, Zhang HE, Polak N, Gorrell MD. Hepatocellular carcinoma: Mouse models and the potential roles of proteases. Cancer Lett. 2016 Apr 1. pii: S0304-3835(16)30208-7
  30. Wilson CH, Zhang HE, Gorrell MD, Abbott CA. Dipeptidyl peptidase 9 substrates and their discovery: current progress and the application of mass spectrometry-based approaches. Biol Chem. 2016 Sep 1;397(9):837-56.
  31. Tyberg A, Seewald S, Sharaiha RZ, Martinez G, Desai AP, Kumta NA, Lambroza A, Sethi A, Reavis KM, DeRoche K, Gaidhane M, Talbot M, Saxena P, Zamarripa F, Barret M, Eleftheriadis N, Balassone V, Inoue H, Kahaleh M. A multicentre international registry of redo per-oral endoscopic myotomy (POEM) after failed POEM. Gastrointest Endosc. 2016 Oct 15. pii: S0016-5107(16)30672-1
  32. Kumbhari V, Peñas I, Tieu AH, De la Serna-Higuera C, Juneja M, Maufa F, Ngamruengphong S, El-Zein MH, Haddad N, Krishnan S, Gonzalez S, Renny PV, Saxena P, Howard L, DiMaio CJ, Buscaglia JM, Perez-Miranda M, Khashab MA. Interventional EUS Using a Flexible 19-Gauge Needle: An International Multicentre Experience in 162 Patients. Dig Dis Sci. 2016 Oct 6.
  33. Bihari C, Anand L, Rooge S, Kumar D, Saxena P, Shubham S, Sukriti, Trehanpati N, Kumar G, Pamecha V, Sharma S, Rastogi A, Kumar A, Sarin SK. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. Hepatology. 2016 Oct;64(4):1273-88.
  34. Gunasingam N, Perczuk A, Talbot M, Kaffes A, Saxena P. Update on therapeutic interventions for the management of achalasia. J Gastroenterol Hepatol. 2016 Aug;31(8):1422-8
  35. Saxena P, El Zein M, Makary M, Kumbhari V, Khashab MA. Submucosal tunneling and en bloc endoscopic resection facilitates laparoscopic transgastric removal of a large GI stromal tumor at the esophagogastric junction. Gastrointest Endosc. 2016 Jul;84(1):179-80
  36. Gandy RC, Barbour AP, Samra J, Nikfarjam M, Haghighi K, Kench JG, Saxena P, Goldstein D. Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. Med J Aust. 2016 Jun 20;204(11):419-22.
  37. Saxena P. Advanced endoscopic therapy in inflammatory bowel disease. J Gastroenterol Hepatol. 2016 Jun;31 Suppl 1:33-4
  38. Saxena P, Khashab MA. New NOTES Clinical Training and Program Development. Gastrointest Endosc Clin N Am. 2016 Apr;26(2):385-400.
  39. Bai P, Ye H, Xie M, Saxena P, Zulewski H, Charpin-El Hamri G, Djonov V, Fussenegger M. A synthetic biology-based device prevents liver injury in mice. J Hepatol. 2016 Jul;65(1):84-94.
  40. Bhutani MS, Koduru P, Joshi V, Saxena P, Suzuki R, Irisawa A, Yamao K. The role of endoscopic ultrasound in pancreatic cancer screening. Endosc Ultrasound. 2016 Jan-Feb;5(1):8-16
  41. Bukhari M, Kumbhari V, Haito-Chavez Y, Chen YI, Ngamruengphong S, Saxena P, Khashab MA. Novel technique to relax the lower esophageal sphincter during challenging peroral endoscopic myotomy (POEM). Endoscopy. 2016;48 Suppl 1:E252
  42. Chen YI, Saxena P, Ngamruengphong S, Haito-Chavez Y, Bukhari M, Artifon E, Khashab MA. Endoscopic ultrasound-guided pancreatic duct drainage: technical approaches to a challenging procedure. Endoscopy. 2016;48 Suppl 1:E192-3.
  43. Khashab MA, El Zein M, Kumbhari V, Besharati S, Ngamruengphong S, Messallam A, Abdelgalil A, Saxena P, Tieu AH, Raja S, Stein E, Dhalla S, Garcia P, Singh VK, Pasricha PJ, Kalloo AN, Clarke JO. Comprehensive analysis of efficacy and safety of peroral endoscopic myotomy performed by a gastroenterologist in the endoscopy unit: a single-centre experience. Gastrointest Endosc. 2016 Jan;83(1):117-25
  44. Sharaiha RZ, Kumta NA, DeFilippis EM, Dimaio CJ, Gonzalez S, Gonda T, Rogart J, Siddiqui A, Berg PS, Samuels P, Miller L, Khashab MA, Saxena P, Gaidhane MR, Tyberg A, Teixeira J, Widmer J. A Large Multicentre Experience With Endoscopic Suturing for Management of Gastrointestinal Defects and Stent Anchorage in 122 Patients: A Retrospective Review. J Clin Gastroenterol. 2016 May-Jun;50(5):388-92.
  45. Fernandez-Ruiz D, Ng WY, Holz L, Ma JZ, Zaid A, Wong YC, Lau LS, Mollard V, Cozijnsen A, Collins N, Li J, Davey GM, Kato Y, Devi Sapna, Skandari R, Pauley M, Manton JH, Godfrey DI, Braun A, Tay SS, Tan SP, Bowen DG, Koch-Nolte F, Rissiek B, Carbone FR, Crabb BS, Lahoud M, Cockburn IA, Mueller SN, Bertolino P, McFadden GI, Caminschi I and Heath WR. Liver-resident memory CD8+ T cells form a front-line defense against malaria liver-stage infections. (2016). Immunity, 45, 889-902 (IF 26).
  46. Wong YC, McCaughan GW, Bowen DG and Bertolino P. CD8 T cell tolerance during liver transplantation. (2016). Clinical and Translational Immunology, in press.
  47. Wang XM, Holz LE, Chowdhury S, Cordoba SP, Evans KA, Gall MG, Vieira de Ribeiro AJ, Zheng YZ, Levy MT, Yu DMT, Yao TW, Polak N, Jolly CJ, Bertolino P, McCaughan GW, and Gorrell MD. The pro-fibrotic role of dipeptidyl peptidase 1 4 in carbon tetrachloride. Immunology and Cell Biology, in press.
  48. Margaret G Gall and Mark D Gorrell (2016) The multifunctional post-proline dipeptidyl peptidase, DPP9, in mice, cell biology and immunity. In: Pathophysiological aspects of proteases. Editors Sajal Chakraborti and Naranjan S. Dhalla. Publisher: Springer, New York.
  49. MD Gorrell, HE Zhang 2016 Dipeptidyl Peptidase 8. In: Choi, S., editor. Encyclopedia of Signaling Molecules. 2nd ed. New York: Springer.
  50. HE Zhang, MD Gorrell 2016 Dipeptidyl Peptidase 9. In: Choi, S., editor. Encyclopedia of Signaling Molecules. 2nd ed. New York: Springer.
  51. N Polak, MD Gorrell 2016 Fibroblast activation protein. In: Choi, S., editor. Encyclopedia of Signaling Molecules. 2nd ed. New York: Springer.
  52. James M Henderson, Hui E Zhang, Natasa Polak, MD Gorrell 2016 Hepatocellular Carcinoma: mouse models and the potential roles of proteases. Cancer Letters, in press. 10.1016/j.canlet.2016.03.047 PMID 27045475
  53. Claire H. Wilson, Hui Emma Zhang, Mark D. Gorrell*, Catherine A Abbott*. Dipeptidyl peptidase substrate discovery: Current progress and the application of mass spectrometry - based approaches. Biological Chemistry. 2016;397: (9) 1437-44 *Equal senior authors.

Book Chapters:
  1. MD Gorrell, HE Zhang 2016 Dipeptidyl Peptidase 8. In: Choi, S., editor. Encyclopedia of Signaling Molecules. 2nd ed. New York: Springer.
  2. HE Zhang, MD Gorrell 2016 Dipeptidyl Peptidase 9. In: Choi, S., editor. Encyclopedia of Signaling Molecules. 2nd ed. New York: Springer
  3. N Polak, MD Gorrell 2016 Fibroblast activation protein. In: Choi, S., editor. Encyclopedia of Signaling Molecules. 2nd ed. New York: Springer.
     

Presentations:

Prof Geoff McCaughan

International

  1. APASL 25th conference - Tokyo, February 2016 Invited Speaker
  2. International APASL 25th conference - Tokyo, February 2016 Invited Speaker
  3. International EASL - OPTIMISE Meeting Invited Speaker
  4. International ILTS Liver Transplant Guidelines Meeting Invited Speaker
  5. International New Zealand Gastroenterology Society Meeting Invited Speaker
  6. International New Zealand Gastroenterology Society Meeting Invited Speaker
  7. National AGW, Adelaide Invited Speaker

National

  1. ANZ Liver Transplant Meeting, Melbourne Invited Speaker

Research Grants

GRANTING BODY AWARDEES PROJECT TITLE YEARS total $$ Years
NHMRC Project Grant 1105238 A/Pr MD Gorrell, Prof GW McCaughan, Prof S Twigg, Prof WW Bachovchin. “DPP4 family proteases as drivers of chronic liver injury”.  $730,040 2016-2020
NHMRC Development Grant 1113842. A/Pr MD Gorrell, Prof GW McCaughan.  “A novel liver cancer therapy targeting tumour stroma”.  $387,902 2016-2017
NHMRC P Bertolino, D Bowen, B Saunders, Laiguan Ng (Role: CIA). A unique network of phagocytic cells at the interface between the liver and peritoneal cavity  $787,521 2015-2018
NHMRC project grant P Bertolino, D Bowen, G McCaughan, K Dwyer (Role: CIA) Unraveling mechanisms of liver transplant tolerance.  $672,000 2015-2018
Rebecca L Cooper Medical Research Foundation Ltd Equipment Grant 10422.  M D Gorrell [supported by Hui Zhang, G W McCaughan, J Gamble, NA Shackel, XJ Zheng, JB Chen, R Liu]. “Developing an improved therapy for type 2 diabetes”.   $25,000 2016
  P Bertolino (Role: CIA). Gene therapy vectors to investigate intrahepatic immunity  $30,000 2016

Contact details for department

Head of Department: Professor Geoff McCaughan

Department/Unit: AW Gastroenterology and Liver Centre
Address:
RPA Hospital
Missenden Road
Camperdown NSW 2050
Telephone: (02) 9515 8578
Facsimile: (02) 9515 5182
Web: http://www.slhd.nsw.gov.au/research/
Email: g.mccaughan@centenary.usyd.edu.au